The Core Allegations
The legal crisis facing Johnson & Johnson centers on devastating allegations that its talc-based products, most notably its baby powder, were contaminated with asbestos, a known carcinogen. For years, plaintiffs have argued that using these products for
feminine hygiene led to the development of ovarian cancer. A smaller but significant number of cases also link the contaminated talc to mesothelioma, a rare and aggressive cancer that affects the lining of the lungs and other organs. While J&J has consistently maintained that its products are safe and that the claims lack scientific merit, juries have delivered mixed but sometimes staggering verdicts against the company, fueling more lawsuits. The company stopped selling its talc-based powder in the US and Canada in 2020 and globally in 2023, citing commercial reasons rather than safety concerns.
An Avalanche of Lawsuits
What began as a trickle of individual lawsuits snowballed into a deluge. As of mid-2026, Johnson & Johnson faced approximately 76,000 claims from people who alleged the company's products caused their cancer. The majority of these cases, nearly 70,000, are consolidated in a federal multidistrict litigation (MDL) in New Jersey. This sheer volume of litigation created an unprecedented challenge for the company. Fighting each case individually became a logistical and financial nightmare, with legal costs soaring and massive jury awards creating significant uncertainty for investors. The constant stream of negative headlines also inflicted immense damage on the company's carefully cultivated family-friendly brand image.
The 'Texas Two-Step' Strategy
In a bid to contain the exploding liability, J&J turned to a controversial legal strategy known as the "Texas two-step." In 2021, the company used a divisive merger law in Texas to split a subsidiary into two new entities. One, the 'new' Johnson & Johnson Consumer Inc., retained the valuable assets. The other, a company called LTL Management, was saddled with all the talc-related liabilities. LTL Management then immediately filed for Chapter 11 bankruptcy. The goal was to halt the tens of thousands of lawsuits and force all claimants into a bankruptcy court, where a global settlement could be negotiated for a fixed amount. However, this strategy was met with fierce opposition from plaintiffs' attorneys, who argued that a highly profitable company like J&J was abusing the bankruptcy system to deny victims their day in court. Federal courts ultimately agreed, dismissing multiple bankruptcy attempts by J&J's subsidiaries, ruling that they were not in the kind of financial distress that bankruptcy is designed to solve.
A Shift to a New Settlement
With its bankruptcy strategy thwarted by the courts, J&J was forced to change tactics. The failure of the "Texas two-step" meant the company once again faced the prospect of defending thousands of individual jury trials, a path it deemed unsustainable. This pressure pushed the company back to the negotiating table, leading to the latest proposal announced in July 2026. Johnson & Johnson has now offered to pay $5.5 billion to resolve the vast majority of the remaining ovarian cancer claims. This move represents a significant pivot, away from complex legal maneuvers and towards a more direct financial resolution to what has become a crisis spanning more than a decade.
What the New Proposal Entails
The new $5.5 billion settlement is structured to resolve nearly all of the 76,000 outstanding ovarian cancer cases. However, the deal is not yet final. It is contingent on getting at least 95% of the claimants to agree to the terms, a high bar for such a large and diverse group of plaintiffs. If the agreement is accepted, J&J plans to make an initial payment of up to $3 billion in 2027, with the remainder paid in subsequent years. While the company continues to deny its products are harmful, this proposal is a clear attempt to achieve what previous efforts could not: finality. For the tens of thousands of women and their families caught in this legal battle, the proposal offers a potential path to compensation without further years of litigation.
